GW
REGN icon

GW & Wade’s Regeneron Pharmaceuticals REGN Stock Holding History

GW & Wade’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$1.96M Sell
2,229
-107
-5% -$88.1K 0.06% 175
2023
Q3 		$1.92M Sell
2,336
-30
-1% -$23.6K 0.07% 164
2023
Q2 		$1.7M Buy
2,366
+13
+0.6% +$10K 0.06% 175
2023
Q1 		$1.93M Sell
2,353
-61
-3% -$46K 0.07% 157
2022
Q4 		$1.74M Buy
2,414
+34
+1% +$25.1K 0.07% 157
2022
Q3 		$1.64M Sell
2,380
-68
-3% -$42.8K 0.08% 147
2022
Q2 		$1.45M Buy
2,448
+39
+2% +$25.4K 0.07% 162
2022
Q1 		$1.68M Sell
2,409
-282
-10% -$178K 0.07% 148
2021
Q4 		$1.7M Buy
2,691
+59
+2% +$36.3K 0.07% 150
2021
Q3 		$1.59M Sell
2,632
-19
-0.7% -$11.8K 0.08% 151
2021
Q2 		$1.48M Buy
2,651
+2
+0.1% +$1.01K 0.07% 151
2021
Q1 		$1.25M Buy
2,649
+1,217
+85% +$593K 0.07% 149
2020
Q4 		$692K Buy
1,432
+464
+48% +$250K 0.04% 169
2020
Q3 		$542K Buy
968
+83
+9% +$50.3K 0.04% 146
2020
Q2 		$552K Buy
+885
New +$502K 0.05% 142

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

GW & Wade's REGN Position: Q4 2023 in Review

GW & Wade reduced its Regeneron Pharmaceuticals (REGN) stake by 4.6% in Q4 2023, selling an estimated $88.1K and leaving 2,229 shares worth $1.96M. The position accounts for 0.06% of the portfolio, ranked #175.

GW & Wade first reported a position in REGN in Q2 2020 and has held it in 15 quarters since. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

  • GW & Wade held 2,229 shares of Regeneron Pharmaceuticals worth $1.96M as of Q4 2023.
  • GW & Wade sold 107 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $88.1K.
  • Regeneron Pharmaceuticals made up 0.06% of GW & Wade's portfolio in Q4 2023, its #175 holding.
  • GW & Wade first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 15 quarters since.
  • 1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on GW & Wade's 13F filing for Q4 2023, filed 8 Feb 2024.